Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: A potential early indicator for technology assessment?

Pearl H Seo, Anthony V. D'Amico, Jack A. Clark, Irving Kaplan, Judith B. Manola, Sonya P. Mitchell, James A. Talcott

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Brachytherapy for early prostate cancer can cause long-term urinary, bowel, and sexual dysfunction. Modifying technique may mitigate complications, but definitive outcome assessment requires long-term follow-up. Although radiation dose plausibly mediates all treatment-related toxicity, short-term symptoms may indicate long-term outcomes. We sought an early indication of whether a modified brachytherapy technique successfully decreased toxicity in the anticipated direction by assessing changes in symptoms and symptom distress 3 months after treatment. In a prospective study of clinically localized prostate cancer using a validated, patient-reported questionnaire, we assessed 85 men, whose primary treatment was brachytherapy alone, prior to treatment and 3 months after the procedure. Twenty-two men received standard ultrasound-guided brachytherapy (SB), and 63 men received magnetic resonance imaging-guided brachytherapy (MB), a technique intended to decrease urinary toxicity by reducing urethral irradiation. Patient age and other sociodemographic variables were similar in the 2 groups. The MB group experienced a greater increase in urinary obstruction/irritation symptoms (P = 0.02) and sexual function distress, but not sexual dysfunction (P = 0.22), whereas the SB group reported a smaller increase in bowel symptoms (P = 0.04) and bowel distress (P = 0.02). We found reduced short-term urinary obstruction/irritation and increased bowel problems after MB consistent with the hypothesized effects of the modified technique, although no obvious mechanism explains the decreased sexual function distress in MB patients. Whether these short-term changes predict long-term outcome differences will require much longer follow-up. However, these results suggest that measuring early symptoms may indicate whether an altered brachytherapy treatment technique has intended favorable consequences, potentially accelerating technology assessment.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalClinical Prostate Cancer
Volume3
Issue number1
StatePublished - Jun 1 2004
Externally publishedYes

Fingerprint

Biomedical Technology Assessment
Brachytherapy
Prostatic Neoplasms
Therapeutics
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Prospective Studies
Radiation

Keywords

  • Bowel dysfunction
  • Quality of life
  • Sexual function
  • Treatment outcomes
  • Urinary incontinence

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms : A potential early indicator for technology assessment? / Seo, Pearl H; D'Amico, Anthony V.; Clark, Jack A.; Kaplan, Irving; Manola, Judith B.; Mitchell, Sonya P.; Talcott, James A.

In: Clinical Prostate Cancer, Vol. 3, No. 1, 01.06.2004, p. 38-42.

Research output: Contribution to journalArticle

Seo, Pearl H ; D'Amico, Anthony V. ; Clark, Jack A. ; Kaplan, Irving ; Manola, Judith B. ; Mitchell, Sonya P. ; Talcott, James A. / Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms : A potential early indicator for technology assessment?. In: Clinical Prostate Cancer. 2004 ; Vol. 3, No. 1. pp. 38-42.
@article{c0638641f8ee4d10be5a1bc17bcfac5f,
title = "Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: A potential early indicator for technology assessment?",
abstract = "Brachytherapy for early prostate cancer can cause long-term urinary, bowel, and sexual dysfunction. Modifying technique may mitigate complications, but definitive outcome assessment requires long-term follow-up. Although radiation dose plausibly mediates all treatment-related toxicity, short-term symptoms may indicate long-term outcomes. We sought an early indication of whether a modified brachytherapy technique successfully decreased toxicity in the anticipated direction by assessing changes in symptoms and symptom distress 3 months after treatment. In a prospective study of clinically localized prostate cancer using a validated, patient-reported questionnaire, we assessed 85 men, whose primary treatment was brachytherapy alone, prior to treatment and 3 months after the procedure. Twenty-two men received standard ultrasound-guided brachytherapy (SB), and 63 men received magnetic resonance imaging-guided brachytherapy (MB), a technique intended to decrease urinary toxicity by reducing urethral irradiation. Patient age and other sociodemographic variables were similar in the 2 groups. The MB group experienced a greater increase in urinary obstruction/irritation symptoms (P = 0.02) and sexual function distress, but not sexual dysfunction (P = 0.22), whereas the SB group reported a smaller increase in bowel symptoms (P = 0.04) and bowel distress (P = 0.02). We found reduced short-term urinary obstruction/irritation and increased bowel problems after MB consistent with the hypothesized effects of the modified technique, although no obvious mechanism explains the decreased sexual function distress in MB patients. Whether these short-term changes predict long-term outcome differences will require much longer follow-up. However, these results suggest that measuring early symptoms may indicate whether an altered brachytherapy treatment technique has intended favorable consequences, potentially accelerating technology assessment.",
keywords = "Bowel dysfunction, Quality of life, Sexual function, Treatment outcomes, Urinary incontinence",
author = "Seo, {Pearl H} and D'Amico, {Anthony V.} and Clark, {Jack A.} and Irving Kaplan and Manola, {Judith B.} and Mitchell, {Sonya P.} and Talcott, {James A.}",
year = "2004",
month = "6",
day = "1",
language = "English",
volume = "3",
pages = "38--42",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms

T2 - A potential early indicator for technology assessment?

AU - Seo, Pearl H

AU - D'Amico, Anthony V.

AU - Clark, Jack A.

AU - Kaplan, Irving

AU - Manola, Judith B.

AU - Mitchell, Sonya P.

AU - Talcott, James A.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Brachytherapy for early prostate cancer can cause long-term urinary, bowel, and sexual dysfunction. Modifying technique may mitigate complications, but definitive outcome assessment requires long-term follow-up. Although radiation dose plausibly mediates all treatment-related toxicity, short-term symptoms may indicate long-term outcomes. We sought an early indication of whether a modified brachytherapy technique successfully decreased toxicity in the anticipated direction by assessing changes in symptoms and symptom distress 3 months after treatment. In a prospective study of clinically localized prostate cancer using a validated, patient-reported questionnaire, we assessed 85 men, whose primary treatment was brachytherapy alone, prior to treatment and 3 months after the procedure. Twenty-two men received standard ultrasound-guided brachytherapy (SB), and 63 men received magnetic resonance imaging-guided brachytherapy (MB), a technique intended to decrease urinary toxicity by reducing urethral irradiation. Patient age and other sociodemographic variables were similar in the 2 groups. The MB group experienced a greater increase in urinary obstruction/irritation symptoms (P = 0.02) and sexual function distress, but not sexual dysfunction (P = 0.22), whereas the SB group reported a smaller increase in bowel symptoms (P = 0.04) and bowel distress (P = 0.02). We found reduced short-term urinary obstruction/irritation and increased bowel problems after MB consistent with the hypothesized effects of the modified technique, although no obvious mechanism explains the decreased sexual function distress in MB patients. Whether these short-term changes predict long-term outcome differences will require much longer follow-up. However, these results suggest that measuring early symptoms may indicate whether an altered brachytherapy treatment technique has intended favorable consequences, potentially accelerating technology assessment.

AB - Brachytherapy for early prostate cancer can cause long-term urinary, bowel, and sexual dysfunction. Modifying technique may mitigate complications, but definitive outcome assessment requires long-term follow-up. Although radiation dose plausibly mediates all treatment-related toxicity, short-term symptoms may indicate long-term outcomes. We sought an early indication of whether a modified brachytherapy technique successfully decreased toxicity in the anticipated direction by assessing changes in symptoms and symptom distress 3 months after treatment. In a prospective study of clinically localized prostate cancer using a validated, patient-reported questionnaire, we assessed 85 men, whose primary treatment was brachytherapy alone, prior to treatment and 3 months after the procedure. Twenty-two men received standard ultrasound-guided brachytherapy (SB), and 63 men received magnetic resonance imaging-guided brachytherapy (MB), a technique intended to decrease urinary toxicity by reducing urethral irradiation. Patient age and other sociodemographic variables were similar in the 2 groups. The MB group experienced a greater increase in urinary obstruction/irritation symptoms (P = 0.02) and sexual function distress, but not sexual dysfunction (P = 0.22), whereas the SB group reported a smaller increase in bowel symptoms (P = 0.04) and bowel distress (P = 0.02). We found reduced short-term urinary obstruction/irritation and increased bowel problems after MB consistent with the hypothesized effects of the modified technique, although no obvious mechanism explains the decreased sexual function distress in MB patients. Whether these short-term changes predict long-term outcome differences will require much longer follow-up. However, these results suggest that measuring early symptoms may indicate whether an altered brachytherapy treatment technique has intended favorable consequences, potentially accelerating technology assessment.

KW - Bowel dysfunction

KW - Quality of life

KW - Sexual function

KW - Treatment outcomes

KW - Urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=3442893254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442893254&partnerID=8YFLogxK

M3 - Article

C2 - 15279689

AN - SCOPUS:3442893254

VL - 3

SP - 38

EP - 42

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -